pentobarbital decreases amounts of vandetanib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Stay away from coadministration with strong CYP3A4 inducers; these medicine lessen exposure to vandetanib by nearly forty%. pentobarbital will lower the level or effect of doxo